Company Overview - Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [2] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers across various molecules, dosage forms, and value tiers [2] Business Model - Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [3] Upcoming Events - The President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to participate in one-on-one investor meetings at the Barclays Global Consumer Staples Conference on September 3rd, 2025 [1]

Company Overview - Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [2] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers [2] Business Model - Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [3] Upcoming Events - The President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on August 12th at 9:00 AM EDT [1]

Core Viewpoint - Perrigo Company plc is set to release its second quarter 2025 financial results on August 6, 2025, and will host a conference call to discuss these results [1] Company Overview - Perrigo Company plc is a leading provider of Consumer Self-Care Products with over a century of experience in delivering high-quality health and wellness solutions primarily in North America and Europe [3] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering accessible self-care solutions that do not require a prescription [3] Business Model - Perrigo's business model is characterized by its complementary businesses, where cash-generative store brand private label offerings support investments in leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [4]

Core Insights - Perrigo Company plc has signed an agreement to sell its Dermacosmetics branded business to Kairos Bidco AB for up to €327 million, which includes €300 million in upfront cash and up to €27 million in potential future milestone payments [1][2] - This transaction is part of Perrigo's 'Three-S' plan aimed at stabilizing, streamlining, and strengthening the organization by focusing on high-growth opportunities [1][2] - The Dermacosmetics business generated approximately €125 million in net sales in 2024, contributing about 5% to Perrigo's adjusted operating income for that year [3] Financial Details - The expected net proceeds from the transaction will be directed towards previously announced capital allocation priorities, including strengthening the company's balance sheet [2] - The transaction is anticipated to close in the first quarter of 2026, pending customary closing conditions and regulatory approvals [3] Strategic Focus - The sale allows Perrigo to sharpen its focus on core self-care categories that align with its One Perrigo model, enhancing its ability to drive sustainable growth and deliver greater value [2] - KKR, the acquiring firm, aims to leverage its global network and operational expertise to accelerate growth in the Dermacosmetics business [2][9]

Core Viewpoint - Perrigo Company plc is optimizing its growth model focused on global Category Leadership and Market Activation to enhance agility, innovation, and sustainable growth, aligning with its 'Three-S' plan [1][2]. Organizational Changes - Roberto Khoury has been appointed as EVP and Chief Commercial Officer to lead global market activation, while the roles of EVP and President CSCI and EVP and President CSCA will be discontinued, with Triona Schmelter leaving the organization [1][4][6]. Growth Model Highlights - The new alignment aims to enhance speed, agility, and scalability, reducing bureaucracy and allowing Perrigo to serve a broader consumer base across various price points [6]. - The growth model has already shown success in the CSCI business and is increasingly effective in the CSCA business, achieving accelerated regulatory milestones and market share gains [6]. Portfolio Optimization - The alignment is designed to unlock value from both brand and store brand portfolios, creating new growth opportunities through enhanced global brand-building capabilities [6]. - Market-empowered activation and strong customer relationships will drive execution excellence in the new model [6]. Leadership Alignment - Roberto Khoury will oversee operating results in both CSCI and CSCA, collaborating closely with David Ball, who is responsible for global category leadership [6]. Financial Guidance - The organizational changes will not affect the full-year 2025 adjusted EPS guidance or reporting segments [6].